A MODEL OF MEASLES VIRUS-INDUCED IMMUNOSUPPRESSION - ENHANCED SUSCEPTIBILITY OF NEONATAL HUMAN PBLS

Citation
A. Tishon et al., A MODEL OF MEASLES VIRUS-INDUCED IMMUNOSUPPRESSION - ENHANCED SUSCEPTIBILITY OF NEONATAL HUMAN PBLS, Nature medicine, 2(11), 1996, pp. 1250-1254
Citations number
33
Categorie Soggetti
Medicine, Research & Experimental",Biology,"Cell Biology
Journal title
ISSN journal
10788956
Volume
2
Issue
11
Year of publication
1996
Pages
1250 - 1254
Database
ISI
SICI code
1078-8956(1996)2:11<1250:AMOMVI>2.0.ZU;2-N
Abstract
Measles virus (MV) still incites one of the most contagious infections of humankind. Despite the development and use of an excellent live at tenuated virus vaccine, over one million infants and children continue to die each year from measles(1-3). The main cause of morbidity and m ortality is virus-induced immunosuppression of lymphocyte function, wh ich allows secondary infections. Here we report an in vivo model for t he study of MV-induced immunosuppression. Human peripheral blood leuko cytes (PBLs) grafted onto mice with severe combined immunodeficiency d isease (SCID mice) to create hu-PBLS-SCID mice produce human IgG that is suppressed by MV infection. Immunosuppression is dependent on the i nvolvement of live virus and is dramatically more severe for PBLs obta ined from newborns than PBLs from adults. Suppression of IgG synthesis by PBLs from newborns occurs as early as ten days after administratio n of MV to hu-PBLS-SCID mice compared with 44 days required for PBLs f rom adults. Further, MV infection of SCID mice reconstituted with PBLs from newborns reduces IgG production 26+/-5-fold (mean+/-1 s.e.m.) as compared with only a 6+/-0.5-fold reduction in adults. MV RNA could b e detected in live human PBLs recovered from SCID mice as long as 110 days after MV infection began. The profound immunosuppression we obser ve in PBLs from infants probably contributes to the morbidity and mort ality observed in infants vaccinated with measles virus. Further, this model should be useful for accessing the potential immunosuppressive abilities of newly isolated field (wildtype) virus isolates and newly designed vaccines containing attenuated MV or subunit vaccines, as wel l as in dissecting the role played by maternal antibodies to MV on the ability of the virus to enhance or abort the virus-induced immunosupp ression.